(TOI) Oncology Institute - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 459m USD | Total Return: 52.5% in 12m
Avg Turnover: 6.99M
Qual. Beats: 1
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Share dilution 32.5% YoY
Interest Coverage Ratio -5.0 is critical
Altman Z'' -6.94 < 1.0 - financial distress zone
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w, Confidence
The Oncology Institute, Inc. (TOI) is a specialized healthcare provider delivering value-based oncology services across the United States. The company operates through three primary segments: Patient Services, Specialty Pharmacy, and Clinical Trials. Its integrated model combines physician services, in-house infusion suites, and radiation therapy with supportive care programs such as palliative care and 24/7 patient assistance.
The business model focuses on community-based clinics, which typically offer lower-cost settings for chemotherapy and immunotherapy compared to traditional hospital environments. By managing an internal specialty pharmacy for oral and self-injectable medications, the company captures a larger share of the patient care continuum while improving medication adherence. The oncology sector is currently transitioning toward value-based care models that prioritize patient outcomes and total cost management over fee-for-service volume.
Investors can further evaluate these financial trends and sector comparisons by visiting ValueRay. Founded in 2007 and headquartered in Cerritos, California, TOI serves adult and senior populations through a network of clinics and mail-order pharmacy services.
- Expansion of value-based care contracts increases predictable per-member per-month revenue
- Specialty pharmacy growth accelerates high-margin oral and self-injectable medication dispensing
- Strategic entry into new geographic markets drives patient volume and scale
- Clinical trial participation rates influence third-party research and development revenue streams
- High labor costs for specialized oncology staff impact consolidated operating margins
| Net Income: -43.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA -3.62 > 1.0 |
| NWC/Revenue: 6.87% < 20% (prev 11.73%; Δ -4.85% < -1%) |
| CFO/TA -0.13 > 3% & CFO -21.8m > Net Income -43.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.02b) vs 12m ago 1.22k% < -2% |
| Gross Margin: 14.82% > 18% (prev 0.15%; Δ 1.47k% > 0.5%) |
| Asset Turnover: 328.5% > 50% (prev 245.8%; Δ 82.72% > 0%) |
| Interest Coverage Ratio: -4.96 > 6 (EBITDA TTM -31.1m / Interest Expense TTM 7.64m) |
| A: 0.22 (Total Current Assets 116.9m - Total Current Liabilities 79.4m) / Total Assets 168.2m |
| B: -1.63 (Retained Earnings -273.9m / Total Assets 168.2m) |
| C: -0.23 (EBIT TTM -37.9m / Avg Total Assets 166.1m) |
| D: -1.48 (Book Value of Equity -273.9m / Total Liabilities 184.5m) |
| Altman-Z'' = -6.94 = D |
| DSRI: 0.88 (Receivables 59.5m/49.7m, Revenue 545.8m/403.2m) |
| GMI: 0.99 (GM 14.82% / 14.70%) |
| AQI: 0.81 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 1.35 (Revenue 545.8m / 403.2m) |
| TATA: -0.13 (NI -43.5m - CFO -21.8m) / TA 168.2m) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 4.59 with a total of 1,666,973 shares traded.
Over the past week, the price has changed by +14.75%,
over one month by +37.84%,
over three months by +54.03% and
over the past year by +52.49%.
Oncology Institute has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy TOI.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7 | 52.5% |
P/S = 0.8409
P/B = 0.7617
Revenue TTM = 545.8m USD
EBIT TTM = -37.9m USD
EBITDA TTM = -31.1m USD
Long Term Debt = 78.6m USD (from longTermDebt, last quarter)
Short Term Debt = 7.40m USD (from shortTermDebt, last quarter)
Debt = 112.3m USD (corrected: LT Debt 78.6m + ST Debt 7.40m) + Leases 26.2m
Net Debt = 82.0m USD (calculated: Debt 112.3m - CCE 30.3m)
Enterprise Value = 540.9m USD (458.9m + Debt 112.3m - CCE 30.3m)
Interest Coverage Ratio = -4.96 (Ebit TTM -37.9m / Interest Expense TTM 7.64m)
EV/FCF = -21.02x (Enterprise Value 540.9m / FCF TTM -25.7m)
FCF Yield = -4.76% (FCF TTM -25.7m / Enterprise Value 540.9m)
FCF Margin = -4.71% (FCF TTM -25.7m / Revenue TTM 545.8m)
Net Margin = -7.97% (Net Income TTM -43.5m / Revenue TTM 545.8m)
Gross Margin = 14.82% ((Revenue TTM 545.8m - Cost of Revenue TTM 464.9m) / Revenue TTM)
Gross Margin QoQ = 14.72% (prev 16.04%)
Tobins Q-Ratio = 3.22 (Enterprise Value 540.9m / Total Assets 168.2m)
Interest Expense / Debt = 6.81% (Interest Expense 7.64m / Debt 112.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -29.9m (EBIT -37.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.47 (Total Current Assets 116.9m / Total Current Liabilities 79.4m)
Debt / Equity = -6.89 (negative equity) (Debt 112.3m / totalStockholderEquity, last quarter -16.3m)
Debt / EBITDA = -2.63 (negative EBITDA) (Net Debt 82.0m / EBITDA -31.1m)
Debt / FCF = -3.19 (negative FCF - burning cash) (Net Debt 82.0m / FCF TTM -25.7m)
Total Stockholder Equity = -13.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.19% (Net Income -43.5m / Total Assets 168.2m)
RoE = -16.70% (Net Income TTM -43.5m / Total Stockholder Equity 260.6m)
RoCE = -11.17% (EBIT -37.9m / Capital Employed (Equity 260.6m + L.T.Debt 78.6m))
RoIC = -31.10% (negative operating profit) (NOPAT -29.9m / Invested Capital 96.3m)
WACC = 7.68% (E(458.9m)/V(571.2m) * Re(8.24%) + D(112.3m)/V(571.2m) * Rd(6.81%) * (1-Tc(0.21)))
Discount Rate = 8.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.11 | Cagr: 15.33%
[DCF] Fair Price = unknown (Cash Flow -25.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.53 | # QB: 1
Revenue Correlation: 99.11 | Revenue CAGR: 23.52% | SUE: 0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.07 | Chg30d=+3.70% | Revisions=+20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.04 | Chg30d=+14.29% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.15 | Chg30d=+34.07% | Revisions=+25% | GrowthEPS=+72.2% | GrowthRev=+31.1%
EPS next Year (2027-12-31): EPS=-0.08 | Chg30d=+0.00% | Revisions=-20% | GrowthEPS=+46.7% | GrowthRev=+24.5%
[Analyst] Revisions Ratio: +25%